Integrated Delivery Network’s Role in Value-Based Agreements for Pharmacy and Medical Benefits Partnership Forum
Implementing value-based reimbursement models for both pharmaceuticals and medical care poses significant challenges and opportunities, and depends on integrated delivery networks (IDNs) to execute the processes and programs. The AMCP Partnership Forum, Integrated Delivery Network’s Role in Value-Based Agreements for Pharmacy and Medical Benefits, took place on Nov. 13-14, 2018 in Arlington, VA.
Value-based care models are designed to support payment based on improved outcomes rather than volume of care provided. AMCP has taken a leading role in advancing the concept, which has potential to improve quality of patient care and lower costs. Previous Partnership Forums have examined different aspects of value-based care. The November Partnership Forum explored issues around establishing value-based agreements between biopharmaceutical companies and IDNs.
The event was made possible with support from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Lilly, MedImpact, Merck, National Pharmaceutical Council, Novo Nordisk, the Pharmaceutical Research and Manufacturers of America, Takeda, and Xcenda.